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ABSTRACT
One of the fundamental principles that underlies tissue-engineering strategies using cell transplan-
tation is that a newly formed tissue must acquire and maintain sufficient vascularization in order
to support its growth. Enhancing angiogenesis through delivery of growth factors is one approach
to establishing a vascular network to these tissues. In this study, we tested the potential of bone mar-
row stromal cells (BMSCs) to modulate the growth and differentiation activities of blood vessel pre-
cursors, endothelial cells (ECs), by their secretion of soluble angiogenic factors. The growth and dif-
ferentiation of cultured ECs were enhanced in response to exposure to BMSC conditioned medium
(CM). Enzyme-linked immunosorbent assays demonstrated that both mouse and human BMSCs se-
creted significant quantities of vascular endothelial growth factor (VEGF) (2.4–3.1 ng/106 cells per
day). Furthermore, eliminating the activity of BMSC-secreted VEGF with blocking antibodies com-
pletely blocked the CM effects on cultured ECs. These data demonstrate that human BMSCs se-
crete sufficient quantities of VEGF to enhance survival and differentiation of endothelial cells in
vitro, and suggest they may be capable of directly orchestrating angiogenesis in vivo.
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INTRODUCTION
THE STUDY OF TISSUE ENGINEERING has developed inresponse to an inadequate supply of organs and tis-
sues for patients requiring organ/tissue replacement.1 One
of the principal objectives of this rapidly evolving field
is to recreate functional, healthy tissues and organs in or-
der to replace tissue lost to disease or inherited deficien-
cies. Transplantation of selected cell populations is a ma-
jor approach to engineering a number of tissue types.
However, the survival of transplanted cells is dependent
on diffusion of nutrients and waste products between the
transplanted cells and the vasculature in the surrounding
host tissue. It has been well established that a functional
vasculature is an essential component of any metaboli-
cally active tissue that has a thickness in excess of a few
millimeters.2 It is the limitations of this mass transport
of nutrients that can lead to loss of more than 95% of
certain transplanted cell types.3 This mass transport is-
sue, furthermore, limits the size of engineered tissues to
a millimeter scale, which is clinically insufficient if one
is to replace a large mass of tissue or a whole organ. To
overcome these limitations, a vascular network must be
established throughout the newly formed tissue in order
to support its growth.
The rapid and transient growth of new capillaries, the
process called angiogenesis, is central to most human life
processes including tissue development, regeneration,
and repair.4 A variety of growth factors that promote the
formation of a new microvasculature have been identi-
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fied,5,6 and they could potentially be utilized to acceler-
ate the ingrowth of blood vessels in developing tissue.
Among these factors, vascular endothelial growth factor
(VEGF) shows promise as a molecule that may enhance
the vascularization of engineered tissue, as it has been
shown to act most specifically on endothelial cells
(ECs).7 Currently, VEGF is being employed in different
model systems to examine its effects on revasculariza-
tion of ischemic tissues and musculocutaneous flaps.8,9
The routes of administration of VEGF in these systems
varies from systemic administration to localized deliv-
ery. Other potential therapeutic uses of VEGF include its
use in systems for delivery of growth factors from dif-
ferent types of polymers.10–12
Interestingly, there is current evidence to suggest that
osteogenic cells and certain types of bone marrow-
derived cells can themselves produce the angiogenic me-
diator VEGF.13,14 This observation raises the possibility
that these mesenchymal cells could potentially regulate
angiogenesis. Multipotent cells derived from bone mar-
row are fast becoming a popular choice as a source of
osteoprogenitor cells for tissue engineering bone.15–17 In
cell cultures generated from suspensions of marrow,
colonies form from a single precursor cell termed the
colony-forming-unit fibroblast (CFU-F).18,19 The prog-
eny of these CFU-F are what have been defined as bone
marrow stromal cells (BMSCs). These BMSCs are ca-
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pable of extensive proliferation and differentiation into
several phenotypes including bone, cartilage, fibrous tis-
sue, adipose tissue, and hematopoiesis-supporting retic-
ular stroma,20 and represent a heterogeneous cell popu-
lation likely containing a range of progenitor cells.
Mesenchymal stem cells (MSCs) similarly are derived
from bone marrow but are isolated from marrow aspi-
rates after purification by Percoll density gradient cen-
trifugation.21 Both of these cell populations have poten-
tial applications in tissue repair strategies.20,22
The hypothesis underlying the current study is that
BMSCs can direct and modulate the growth and differ-
entiation of ECs. The specific goals of the present study
were to determine whether BMSCs produce angiogenic
factors capable of enhancing the proliferation and dif-
ferentiation of endothelial cells. The results of these stud-
ies indicate that BMSCs secrete sufficient quantities of
VEGF to enhance the growth and differentiation of en-
dothelial cells in an in vitro model of angiogenesis.
MATERIALS AND METHODS
Isolation and culture of BMSCs and 
MC3T3-E1 cells
Human bone marrow was collected, with University
of Michigan institutional review board approval as pre-
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FIG. 1. Effect of BMSC CM on endothelial cell survival. ECs were cultured under three different conditions: medium alone,
medium plus VEGF, and medium plus BMSC CM. Cell survival was measured as a percentage of the initial number of adher-
ent cells per 3200 field. Values represent means 6 standard error of the mean (SEM) calculated from three dishes. *p , 0.05
when compared with medium alone.
viously described, from patients undergoing iliac bone
graft procedures.23 Briefly, marrow was placed in ice-
cold a-MEM (Life Technologies, Grand Island, NY) with
sodium heparin (100 U/mL; Fisher Scientific, Fair Lawn,
NJ) and centrifuged at 1000 rpm for 10 min, and the cell
pellet was resuspended in fresh a-MEM. All preparations
were pipetted repeatedly to break up cell aggregates. Sub-
sequently, marrow cell suspensions were passed consec-
utively through 16.5- and 20.5-gauge needles before cul-
ture. Cells were cultured in a-MEM, 2 mM glutamine,
penicillin (100 U/mL), streptomycin sulfate (100 mg/mL)
(Biofluids, Rockville, MD), and 10% fetal bovine serum
(FBS; Life Technologies) supplemented with 1028 M
dexamethasone (Dex; Sigma, St. Louis, MO) and 1024 M
L-ascorbic acid-phosphated magnesium salt n-hydrate
(AscP; Wako, Osaka, Japan).
Mouse bone marrow stromal cells (mBMSCs) were
collected from B57Blk6 mice. Mice were sacrificed and
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washed in 80% ethanol. The limbs of each mouse were
removed at their articulation and placed in a 100 3
20 mm2 style tissue culture dish (Falcon; BD Diagnostic
Systems, Franklin Lakes, NJ) with Hanks’ balanced 
salt solution (HBSS; Life Technologies, Rockville, MD)
and 2% penicillin–streptomycin (P/S) (GIBCO-BRL,
Gaithersburg, MD). Bone marrow was flushed from the
femur and humerus bones with medium containing 20%
FBS, 1% P/S, and amphotericin B (Fungizone, diluted
1:1000). All flushed marrow was then placed in 75-mm2
tissue culture flasks (marrow from two mice per flask)
(Corning Life Sciences, Corning, NY) with medium con-
taining 20% FBS, 1% P/S, Fungizone (diluted 1:1000),
and 1028 M Dex. After 1 week in 75-mm2 tissue culture
flasks incubated at 37°C in a humidified atmosphere of
95% air and 5% CO2, half of the medium volume was
replaced with fresh medium. Three days after this initial
change in medium, cells were passaged. Cells were main-
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FIG. 2. (a–d) Endothelial cell sprouting seen after induction with VEGF. ECs form sprouts, indicated by carets, after induc-
tion with rhVEGF. Day represents number of days after initial seeding of cells. The number of sprouts increases with time of
exposure to VEGF. Original magnification: 3100.
tained in a-MEM containing 10% FBS, 1% P/S, and
1028 M Dex.
Preosteoblastic MC3T3-E1 cells were a generous gift
from M. Kumegawa (Josai Dental University, Sakado,
Saitama, Japan). These cells were cultured in a-MEM
containing 10% fetal calf serum and 1% P/S.
Normal human mesenchymal stem cells (hMSCs),
generated via a Poietics system (BioWhittaker Cambrex,
Walkersville, MD), were cultured in human mesenchy-
mal stem cell growth medium (Clonetics, San Diego,
CA) as directed by the supplier.
Endothelial cell survival and capillary 
tube assays
Human dermal microvascular endothelial cells 
(HDMECs, 3.0 3 105; Cell Systems, Kirkland, WA)
were suspended in endothelial cell growth medium
(EGM-MV; Clonetics) and placed into 60-mm2 tissue
culture dishes (Corning Life Sciences). Dishes were
coated 24 h earlier with 2.5 mL of a gelled solution of
bovine dermal type I collagen (Vitrogen 100; Cohesion,
Palo Alto, CA). Cells were allowed to attach for 24 h,
plates were washed to remove unattached cells, and cells
were cultured in EGM-MV, supplemented with either re-
combinant human VEGF165 (rhVEGF165, 50 ng/mL; In-
tergen, Purchase, NY), BMSC conditioned medium
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(CM), or endothelial basal medium (EBM-2; Clonetics)
with 1% FBS used as the control medium. All BMSC
CM used in the survival and capillary tube assays was
collected from cultures of human BMSCs isolated as de-
scribed earlier. The BMSC CM was collected and con-
centrated 10-fold by centrifugation with an UltraFree-15
centrifugal filter device, which had a membrane with a
nominal molecular mass limit of 5 kDa (Millipore, Bed-
ford, MA). The concentrated medium was then brought
back to a 13 concentration by diluting it 1:10 with EGM-
MV (normal EC growth medium) before addition to EC
cultures. The control medium (not exposed to BMSCs)
was similarly concentrated and diluted with EGM-MV
before use. Each respective medium was exchanged for
fresh medium, of the same type, every 2 days for the du-
ration of the experiment. Every other day for 9 or 10 days,
the number of cells in 8 random high-power fields
(3200), as well as the number of capillary-like sprouts
in 10 random high-powered fields (3100), were counted.
Criteria for counting sprouts have been previously de-
scribed.24 The criteria used to define a sprout in these as-
says were at least two endothelial cells connecting to one
another by an elongated branching structure from one or
both of the cells. The data were obtained from triplicate
dishes per condition at each time point.
In certain experiments, ECs were cultured in BMSC
CM containing mouse anti-human VEGF Ab-3 (JH121;
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FIG. 3. Effects of BMSC CM on EC sprouting. EC sprouting is used as a marker of differentiation, and is measured as the av-
erage number of sprouts per 3100 field. Values represent means 6 SEM (n 5 3). *p , 0.05 when compared with medium alone.
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Neomarkers, Fremont, CA) or mouse IgG1 Ab-2 (Neo-
markers). The anti-VEGF antibody used in this assay in-
hibits the biological activity of human VEGF, and inhibits
the biological activity of mouse, rat, and rabbit VEGF as
well (Neomarkers, company literature). EC survival and
sprout formation were measured as described above.
Quantitative measurement of VEGF in CM
At approximately 95% confluence, hBMSCs, mBMSCs,
hMSCs, and MC3T3-E1 cells (all between passages 5
and 7) were washed twice with HBSS and placed in
EBM-2 with 1% fetal bovine serum overnight (16 h). The
medium was then collected and concentrated 10-fold with
an UltraFree-15 centrifugal filter device (Millipore). Cell
counts were obtained with a Coulter counter at the time
of medium collection to normalize VEGF secretion to
cell number. The VEGF concentration in hBMSC CM
was measured by a solid-phase enzyme-linked immuno-
sorbent assay (ELISA) (R&D Systems, Minneapolis,
MN) designed to measure VEGF levels in supernatants,
serum, and plasma. VEGF concentration was measured
in picograms per milliliter, and normalized per million
cells (based on cell counts done using a Coulter counter
at the time of collection of CM). The minimum detectable
concentration of VEGF in this assay is 5.0 pg/ml.
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FIG. 5. VEGF antibody blocking of BMSC CM effects on EC survival. ECs were cultured under four different conditions:
medium alone, medium plus VEGF antibody, medium plus BMSC CM plus VEGF antibody, and medium plus BMSC CM plus
control Ab (IgG). Cell survival is measured as a percentage of the total number of cells initially adherent, and values represent
means 6 SEM (n 5 3). Original magnification: 3200. *p , 0.05 when compared with CM plus VEGF Ab.
FIG. 4. Quantitative measurement of VEGF in medium (in
human BMSC CM, human MSC CM, mouse BMSC CM, and
CM from an osteoblastic cell line, MC3T3-E1). ELISA was
used to determine concentrations of VEGF. Concentrations
were normalized to cell number and secretion time. Values rep-
resent means 6 SEM.
Statistical analysis
The statistical analyses were performed with Sigma
Stat (Sigma). Descriptive analyses were performed ini-
tially, followed by the use of Student t tests or one-way
ANOVA, according to the experimental design.
RESULTS
Effects of BMSC CM on EC survival 
and differentiation
To test whether BMSCs influence EC survival and dif-
ferentiation, we cultured ECs in the presence of BMSC
CM or the known proangiogenic factor VEGF. We com-
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pared the survival and differentiation effects of BMSC
CM with the effects of VEGF. The addition of VEGF to
EC cultures enhanced endothelial cell survival on colla-
gen gels, whereas total cell number declined over time if
cells were cultured in basal medium alone (Fig. 1). The
addition of BMSC CM to endothelial cell cultures en-
hanced endothelial cell survival after 6 days in culture.
At all time points after 7 days, the percentage of the ini-
tial number of ECs that remained in culture was signifi-
cantly (p , 0.05) higher in cultures supplemented with
BMSC CM, when compared with survival of endothelial
cells cultured in nonsupplemented medium.
The ability of ECs to organize into sprouting structures
is a hallmark of EC differentiation in vitro,25,26 and we
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FIG. 6. Effect of VEGF blocking on BMSC CM promotion of EC differentiation. Photomicrographs of representative 3100
fields were taken of ECs in culture (a–d) and the number of sprouts per 3100 field was quantified (e). Four experimental con-
ditions were tested: medium alone (a), medium plus VEGF (b), medium plus BMSC CM plus VEGF Ab (c), and medium plus
BMSC CM plus IgG Ab (d). Values in (e) represent means 6 SEM (n 5 3). *p , 0.05 when compared with medium alone.
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used this marker to test the effects of BMSC CM on EC
differentiation. We first tested our model system for in
vitro angiogenesis by adding VEGF to EC cultures as 
a stimulus for EC differentiation. Over a 10-day time
course during which VEGF was added to EC cultures,
organization of ECs into capillary-like networks was
clearly seen (Fig. 2). Small-scale screening assays utiliz-
ing different concentrations of VEGF indicated that 
50 ng/ml gives the most robust sprouting response, par-
ticularly at late time points (i.e., 10–14 days) (data not
shown), and this concentration was used as a positive
control in all studies. Addition of BMSC CM to collagen
cultures led to a significant enhancement (p , 0.05) in
endothelial cell sprouting, beginning on day 5, when
compared with levels of sprouting in cultures grown in
basal medium alone. This effect continued for the 9-day
duration of the experiment (Fig. 3).
Role of VEGF in BMSC CM effects on ECs
VEGF is a potent angiogenic factor produced by a va-
riety of cell types and has been previously noted to be
secreted from bone marrow-derived cells.13,14 We inves-
tigated whether the effects of BMSC CM on ECs could
be partially or totally attributed to secreted VEGF. First,
ELISAs were performed with conditioned medium from
four different types of stromal cells cultured overnight
(,16 h) in basal medium containing 1% serum to con-
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firm that the stromal cells used in these studies secreted
VEGF. Human BMSCs, human mesenchymal stem cells,
and mouse BMSCs all secreted VEGF at rates between
2.4 and 3.1 ng/106 cells per day. A fourth cell type, the
preosteoblastic cell line MC3T3-E1, did not secrete any
detectable VEGF during this time period (Fig. 4). Quan-
tifying VEGF in this manner also allowed us to make an
estimate of the amount of VEGF that was contained in
the CM, before addition of CM to ECs, in the survival
and capillary tube assays. On the basis of the data quan-
tifying secreted VEGF from hBMSCs, BMSC CM con-
tained VEGF at 2 ng/mL. Next, we determined whether
VEGF in BMSC CM was responsible for the survival and
differentiation effects seen with ECs. To do this, VEGF
blocking and control antibodies were added to BMSC
CM before addition of the medium to EC cultures. VEGF
blocking antibodies completely eliminated the positive
effects of BMSC CM on EC survival, whereas the con-
trol antibody had no effect (Fig. 5).
VEGF antibodies were also employed in the capillary
tube assay to confirm the role of BMSC-secreted VEGF
in EC differentiation. As expected, culture of ECs in ba-
sal medium led to little EC differentiation (Fig. 6a) and
stimulation of cultures with VEGF produced the greatest
magnitude of sprouting (Fig. 6b). BMSC CM plus con-
trol antibodies again demonstrated increased EC sprout-




sprouting was greatly reduced when VEGF-blocking an-
tibodies were added to BMSC CM before addition to EC
cultures (Fig. 6c). Quantification of these findings indi-
cated that the levels of endothelial cell sprouting with
BMSC CM were actually reduced to a lower level than
control, after addition of VEGF Ab (Fig. 6e).
DISCUSSION
In these studies, we investigated the hypothesis that
BMSCs could direct and modulate the growth and dif-
ferentiation of ECs. We have shown that BMSCs from
different sources (mouse/human) secrete VEGF. Fur-
thermore, hBMSCs secrete sufficient factors to enhance
the proliferation and differentiation of ECs in three-
dimensional collagen cultures. Finally, antibody block-
ing experiments confirmed that the effects of hBMSC
CM on ECs is either completely attributable to secreted
VEGF, or at least requires the action of secreted VEGF.
It has been previously reported that different types of
osteogenic cells can be induced to express VEGF13,27 and
that bone marrow cells secrete VEGF.14 However, this
is the first report of secretion of VEGF from this popu-
lation of cells, defined as BMSCs and characterized as
previously described.17 VEGF in conditioned medium
was measured by an ELISA and cells were counted af-
ter collection of conditioned medium to quantify the
amount of VEGF secreted on a per-cell number basis.
Quantification on a per-cell transplanted basis could po-
tentially be useful in cell transplantation protocols in
which the aim is to utilize these cells as a source of an-
giogenic factors. It could be of even greater significance
if the plan is to augment secreted levels of growth fac-
tor from BMSCs with exogenous delivery of VEGF. A
significant finding is that BMSCs secrete a sufficient
quantity of functional angiogenic factors capable of en-
hancing the survival and differentiation of ECs. Further-
more, the amounts of VEGF secreted correlate with the
mitogenic activity of VEGF.28 The sprouting assay used
in this study is an in vitro model for angiogenesis in
which ECs in culture have been shown to produce tubu-
lar networks almost identical, by light and electron 
microscopy, to capillary vascular beds in vivo.25 In a sim-
ilar system,29 it has also been shown that various con-
centrations of VEGF induce proliferation and much
greater differentiation of endothelial cells into capillary
tubes.30 In our studies, although hBMSC CM did not en-
hance proliferation and differentiation to levels seen
when exogenous VEGF was added, there was a statisti-
cally significant enhancement of proliferation and dif-
ferentiation over negative control levels. The decreased
effect of BMSC CM was likely related to the lower con-
centration of VEGF in CM (2 ng/ml), as compared with
the VEGF control (50 ng/ml). There have been reports
of inducing angiogenesis through the transplantation of
other types of bone marrow-derived cells14,31 and sug-
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gestions for these cells to be used therapeutically for an-
giogenesis.32,33 However, there have not been any reports
quantifying the amount of VEGF secreted by hBMSCs,
or describing their effects on EC survival and differenti-
ation in the capillary tube assay.
The role of VEGF in BMSC CM-induced EC survival
and differentiation was determined by antibody blocking
experiments. Where previous studies have reported that
supernatant from cultured bone marrow cells can enhance
proliferation of ECs in vitro,14,31 our results further in-
dicate that their effects are either completely attributable
to secreted VEGF, or at least requires the action of se-
creted VEGF. VEGF-blocking antibodies eliminated the
enhanced survival and differentiation found with the ad-
dition of hBMSC CM. We propose two possible mech-
anisms to explain this observation. The first is that VEGF
secreted from hBMSCs is solely responsible for the
heightened activity of ECs in the presence of CM. The
other possibility is that VEGF functions in concert with
additional secreted factors in order to enhance the sur-
vival and differentiation of ECs. Additional assays for
detection of other growth factors and cytokines need to
be carried out in order to better differentiate between
these possible mechanisms.
In summary, we have demonstrated that hBMSCs 
secrete VEGF capable of enhancing the growth and dif-
ferentiation of endothelial cells in an in vitro model of
angiogenesis. The secreted VEGF is necessary, but not
necessarily sufficient, for hBMSC CM to enhance EC
survival and differentiation. This finding suggests
hBMSC transplantation may allow the rapid achievement
of vascularization of engineered tissues, although further
in vivo studies are required to confirm this possibility.
The finding of these studies also further the current un-
derstanding of the interactions between ECs and osteo-
progenitor cells.
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